Haematology - Multiple Myeloma
A list of our early phase haematology (Multiple Myeloma) trials which are open to recruitment at University College London Hospitals.
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
ProMMiseA Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies | |
|---|---|
| IRAS Number: | 1003553 |
| Principal Investigator: | Dr. Rakesh Popat |
| Drug Class/ Treatment: | Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate) |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
DTP3Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NFκB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3 | |
|---|---|
| IRAS Number: | 1004023 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | DTP3 (GADD45β/MKK7 Inhibitor) |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
79635322MMY1001Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | |
|---|---|
| IRAS Number: | 1006143 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | JNJ-79635322 - Trispecific Antibody |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
TCD17710First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell mat ration antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory lightchain amyloidosis (RRLCA) | |
|---|---|
| IRAS Number: | 1007232 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | SAR445514 (NK-Cell Engager (NKCE) Targeting BCMA) |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
BGB-11417-105A phase 1b/2 Dose-Escalation and Cohort-Expansion Study to determine the Safety and Efficacy of BGB11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | |
|---|---|
| IRAS Number: | 1005586 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | BGB-11417 (BCL2 Inhibitor) Monotherapy, In Combination with Dexamethasone and In Combination with Dexamethasone/Carfilzomib |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
M24-108A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma | |
|---|---|
| IRAS Number: | 1006892 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | ABBV-383 (B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody) |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
on-hold to recruitment
| CA057-003 (CC-92480) An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma | |
|---|---|
| IRAS Number: | 1005265 |
| Principal Investigator: | Dr Rakesh Popat |
| Drug Class/ Treatment: | Mezigdomide (CC-92480) - Cereblon (CRBN) E3 Ligase Modulating Drug (CELMoD) |
| Patient Population: | Multiple Myeloma |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
